Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Firy Inc. (FIRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Firy Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Firy Inc. trades at $8.54 (market cap $133.29M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 299.3× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FIRY | |
|---|---|---|
Market Cap | $39.89B | $133.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $12.45 |
52-Week Low | $278.09 | $2.28 |
Enterprise Value | $38.15B | $76.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FIRY (formerly Skillz) trades at $8.54, down 3.06% today, amid a recent rebrand and mixed quarterly results. The stock shows a bullish technical signal with support near $8 and resistance at $9, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; while technicals suggest near-term strength, fundamental challenges from sustained unprofitability and high cash burn pose significant risks. Analyst sentiment is mixed with 60% hold ratings, reflecting uncertainty over the company's turnaround amid competitive pressures in mobile gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
